title: The long noncoding RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance of lung adenocarcinoma A549 cells.
abstract: Long non-coding RNAs (lncRNAs) are a family of non-protein-coding RNAs that might affect Lung adenocarcinoma (LAD) chemo-resistance and most of them could be used as biomarkers and therapy targets. However, the potential function of lncRNA ANRIL contributed paclitaxel chemo-resistance in LAD is still unknown. This study aimed to observe the expression of ANRIL in LAD, evaluate its biological role in the resistance of LAD cells to paclitaxel and explore the apoptosis role in the ANRIL associated mechanism. Our results showed that ANRIL functioning as a potential oncogene was up-regulated in LAD, and promoted the acquisition of chemo-resistance in paclitaxel partly through the mitochondrial pathway by modulating the expression of apoptosis-related protein cleaved-PARP and Bcl-2. These findings might improve LAD patients' paclitaxel treatment and made ANRIL to be a new target for paclitaxel-based chemotherapy in LAD.
authors.affiliation: Department of Thoracic Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.
authors.forename: Ran
authors.initials: R
authors.lastname: Xu
authors.affiliation: Department of Thoracic Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.
authors.forename: Yuqiang
authors.initials: Y
authors.lastname: Mao
authors.affiliation: Department of Thoracic Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.
authors.forename: Kuanbing
authors.initials: K
authors.lastname: Chen
authors.affiliation: Department of Thoracic Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.
authors.forename: Wei
authors.initials: W
authors.lastname: He
authors.affiliation: Department of Thoracic Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.
authors.forename: Wenjun
authors.initials: W
authors.lastname: Shi
authors.affiliation: Department of Thoracic Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Han
mesh_terms: D000072283:A549 Cells; D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D014408:Biomarkers, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008297:Male; D009857:Oncogenes; D017239:Paclitaxel / Q000494:pharmacology*; D011379:Prognosis; D062085:RNA, Long Noncoding / Q000235:genetics*; D015996:Survival Rate
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; C561518:CDKN2B antisense RNA, human; D062085:RNA, Long Noncoding; D017239:Paclitaxel
keywords: ANRIL; chemotherapy resistance; long noncoding RNA; lung adenocarcinoma; paclitaxel